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Background: To compare the diagnostic yield of echocardiography and cardiovascular
MRI (CMR) to detect structural sources of embolism, in patients with ischemic stroke
with a secondary analysis of non-stroke populations.
Methods and Results: We searched MEDLINE/Embase (from 01.01.2000 to
24.04.2021) for studies including CMR to assess prespecified sources of embolism.
Comparison included transthoracic and/or transesophageal echocardiography. Two
authors independently screened studies, extracted data and assessed bias using the
QUADAS-2 tool. Estimates of diagnostic yield were reported and pooled. Twenty-seven
studies with 2,525 patients were included in a study-level analysis. Most studies had
moderate to high risk of bias. Persistent foramen ovale, complex aortic plaques, left
ventricular and left atrial thrombus were the most common pathologies. There was no
difference in the yield of left ventricular thrombus detection between both modalities for
stroke populations (4 studies), but an increased yield of CMR in non-stroke populations
(28.1 vs. 16.0%, P < 0.001, 10 studies). The diagnostic yield in stroke patients for
detection of persistent foramen ovale was lower in CMR compared to transoesophageal
echocardiography (29.3 vs. 53.7%, P < 0.001, 5 studies). For both echocardiography
and CMR the clinical impact of the management consequences derived from many of
the diagnostic findings remained undetermined in the identified studies.
Conclusions: Echocardiography and CMR seem to have similar diagnostic yield
for most cardioaortic sources of embolism except persistent foramen ovale and
left ventricular thrombus. Randomized controlled diagnostic trials are necessary to
Meinel et al. Cardiovascular MRI and Echocardiography in Stroke
understand the impact on the management and potential clinical benefits of the
assessment of structural cardioaortic stroke sources.
Registration: PROSPERO: CRD42020158787.
Keywords: cardiac MRI, echocardiography, ischemic stroke, diagnostic work up, cardioaortic embolism
INTRODUCTION
Emboli from the heart and great supraaortic arteries account
for about 25% of acute ischemic stroke (AIS) (1). The
most frequently used diagnostic tests to identify structural
cardioembolic sources (see Table 1 for potential sources) (2) are
transthoracic (TTE) or transesophageal echocardiography (TEE).
However, the number needed to screen to change management
on an evidence-based principle is relatively high (3, 4) and there
is a notorious debate about the yield, usefulness and optimal
patient selection regarding echocardiography in AIS patients
(5–7). Hence, the effectiveness of routine echocardiography
in unselected AIS patients to optimize treatment selection
for prevention of recurrent cardiovascular events was deemed
uncertain by the 2019 update of the guidelines for the
management of acute stroke with a moderate evidence level
supporting this statement (5).
Cardiovascular magnetic resonance imaging (CMR) has the
ability to identify intraventricular thrombi and thrombi in the
left atrium (LA) and left atrial appendage (8). Furthermore,
ulcerated/complex aortic arch atherosclerotic plaques, left
ventricular non-compaction cardiomyopathy, and other
cardiac structural abnormalities (i.e., LA fibrosis, inherited
cardiomyopathy, infiltrative cardiopathy) are potentially relevant
findings on CMR with consequences regarding AIS patient
management (9–13). Additionally, CMR offers the ability to
detect subendocardial or transmural left ventricular scars from
recent or previous myocardial infarction. The latter is important
as wall motion abnormalities may promote intracardiac
thrombus formation and serve as a cardioembolic source
of strokes, and may have long-term prognostic implications
(14–16). As outlined in a previous narrative review, CMR may
represent a potential diagnostic method in patients after embolic
stroke with undetermined etiology or—more precisely—of
unknown source (ESUS) although heterogeneity in indication
strategies, accessibility and feasibility of CMR have to be taken
into account (17).
In view of these observational reports and owing to the lack
of randomized data, we conducted a systematic review to report
on the diagnostic yield of CMR and echocardiography (TTE
and/or TEE) as diagnostic strategy for work-up of structural
cardio-aortic sources of embolism in AIS patients.
METHODS
Registration and Data Availability
Statement
Performed according to the Preferred Reporting Items for
Systematic Reviews and Meta-analyses guideline for Diagnostic
Test Accuracy studies (18). The protocol has been published prior
to performing the analysis (PROSPERO:CRD42020158787).
Data will be shared upon request from any qualified investigator
for the purposes of replicating results.
Study Eligibility Criteria
Eligible studies included adults (older than 16 years) and all
ethnic groups reporting on established, predefined structural
high-risk sources embolism in the context of AIS (Table 1)
(19, 20). For the primary analysis, only patients in the AIS
setting who underwent both, CMR and echocardiography during
hospitalization or later, were included. In a secondary analysis,
studies in non-stroke populations were included when they
reported the predefined high-risk sources. We excluded studies
reporting on congenital heart diseases (post-hoc exclusion after
registration). We included peer-reviewed, original studies only.
Since state-of-the-art CMR was used in the last two decades,
we only considered publications beyond January 1st, 2000 for
analysis. We selected the study with the larger sample size in case
of studies with duplicate data. We excluded studies with less than
five patients undergoing both diagnostic methods.
Data Sources and Searches
We searched PubMed/EMBASE using a predefined search
strategy combining MeSH terms and keywords with
the concepts of CMR, echocardiography and AIS (see
Supplementary Material and Table 2 for full details). We
used additional references from papers if relevant information
was provided. We included articles published in English,
German, French or Spanish between January 1st, 2000 and April
24th, 2021.
Study Selection
Two independent researchers (TRM and AE) assessed the
eligibility based on title and abstract using the covidence
online review tool. Full-text manuscripts were obtained for all
eligible studies before full-text review. Any differences regarding
eligibility were resolved by consensus.
Data Collection Process and Data Items
We extracted data on study characteristics (study design,
publication year, sample size, target condition) and study
population characteristics (country, inclusion/exclusion criteria).
We also collected data on CMR and echocardiography
techniques, such as magnetic field strength, use of contrast agent,
time interval between tests, and rate of pathological findings. We
extracted study data on predefined forms using study-specific
definitions for the predefined target condition(s).









































TABLE 1 | Cardioaortic sources of embolism, management implications, and diagnostic tests.
Target conditions (Potential) management
implications






CMR TTE TEE CTA
High-risk sources
of embolism
Left atrial (appendage) thrombus Anticoagulation, (Left atrial
appendage occlusion),
Prolonged screening for atrial
fibrillation
++ + +++ ++ 3–16% Yes Dense spontaneous echo
contrast (SEC) similar to
thrombus
Left ventricular thrombus:






+++ ++ (CE) ++ (CE) ++ 1–5%
2–4%








? ++ +++ ? 3%
1–2%
<1%
Yes Clinical signs including fever,
heart murmur, etc. Risk
increases with size and
mobility
Non-thrombotic masses, e.g.,
Myxoma or other tumors
(Surgery) +++ + ++ ++ <1% Yes
Valve thrombosis Anticoagulation, (surgery) ? ++ +++ + <1%
Aortic dissection (Surgery) ++ - ++ +++ <1%





+ ++ +++ + <1%
Persistent foramen ovale and/or Atrial
septal aneurysm









Complex aortic plaques Statin (surgery, dual antiplatelet
therapy)





LV-aneurysm, transmural scarring Anticoagulation +++ ++ ++ ++ 1%




+++ ++ ++ ++ <1% Absolute risk unclear
Left atrial volume, morphology and
function
(Long-term monitoring for atrial
fibrillation)
+++ + ++ ++ 20–25%
Aortitis Antiinflammatory treatment +++ + ++ + <1%
Uncertain risk Structural Correlates of atrial
dysrhythmias (e.g., atrial fibrosis)
(Prolonged rhythm monitoring,
anticoagulation)
+++ - - -
Spontaneous echo contrast “smoke” (Anticoagulation) + - +++ + 2–15% Higher risk with dense SEC
High grade valve
disease/calcifications



































































































































































































































































































































































































































































































































































































































































































































































































































Risk of Bias in Individual and Across Studies
We compared data items, study design strengths and weaknesses.
We assessed the risk of bias at the study level using the QUADAS-
2 bias assessment tool with study-specific items for studies
included in the quantitative analysis.
Index Test and Reference Standard, Study Endpoints
Due to the diverse structural sources with differing gold
standards for each pathology, we chose diagnostic yield as
the primary endpoint. Diagnostic yield was defined as the
proportion of patients with a specific pathology on CMR
or echocardiography. Sensitivity and specificity of CMR as
compared to echocardiography were defined as secondary
outcome. For this analysis, CMR was chosen as the index
test and echocardiography defined as the reference. Other
endpoints reported in qualitative manner included feasibility of
CMR, and change of management in AIS patients according to
imaging findings.
Synthesis of Results and Summary Measures
We used McNemar test for paired data to determine differences
in diagnostic yield using Stata (StataCorp. 2019. Stata Statistical
Software: Release 16. College Station, TX: StataCorp LLC).
Measures of diagnostic accuracy, sensitivity and specificity of
CMR vs. echocardiography were calculated for all studies based
on reported cases with the identified pathology. Forest plots
were generated using Review Manager version 5.3 (RevMan,
Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014).
RESULTS
We identified 1,422 publications, of which 210 were selected for
full-length review (Figure 1). Of these, 27 articles fulfilled the
inclusion criteria and were included in the quantitative meta-
analysis (8, 14, 21–45), further 19 studies in the qualitative
report. Most studies had moderate to high risk of bias, i.e.,
bias relating to patient selection (non-stroke populations, highly
selected stroke subgroups), to applicability, flow and timing of
data acquisition (long intervals between both tests, blinding, non-
random sequence), see Supplementary Material for full details.
Study characteristics of the included studies are presented in
Supplementary Table 1. All were single center, academic cohort
studies published between 2000 and 2020 with half of them being
prospective. A total of 2,525 patients were included with study
sizes from 16 to 316 patients. Eleven of the 27 studies exclusively
included AIS patients, while the others mostly addressed patients
with known cardiac pathologies (myocardial infarction, reduced
ejection fraction, high risk for cardiac thrombus).
We report details on CMR and echocardiography methods
(12/27 TEE, 11/27 TTE, 4 both; use of contrast in some studies)
in Supplementary Table 1. Time interval between CMR and
echocardiography ranged between 0 and 89 days and was unclear
in 5/27 studies.
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TABLE 2 | Search strategy.

















Concept 3 (ischemic stroke) “Stroke”[Mesh] OR
“Cerebrovascular Disorders”[MeSh] OR





Date filter “2001/01/01”[PDAT]: “2021/04/24”[PDAT]
AND
Further filters “humans”[MeSH Terms] AND (English[lang] OR
French[lang] OR German[lang] OR
Spanish[lang]
Combination of Medical Subject Headings and keywords for the concepts of cardiac MRI,
echocardiography and ischemic stroke.
Diagnostic Yield (High-Risk Sources of
Embolism)
The diagnostic yield of CMR as compared to echocardiography
to identify prespecified structural high-risk and medium-
risk sources of embolism was similar (Table 3). Overall,
persistent foramen ovale (PFO), complex aortic plaques, left
ventricular (LV) and LA and LAA thrombus were the most
common pathologies.
In stroke populations, the only pathology with a significant
difference in diagnostic yield was PFO (CMR 29.3% vs.
echocardiography 53.7%, P < 0.001). Some groups have reported
reliable assessment with contrast-enhanced CMRusing dedicated
perfusion protocols (29), but overall TEE is the method of choice
when PFO should be ruled out (23, 43, 44).
There was no difference in the yield of LV thrombus
detection between both modalities for stroke populations.
However, there was an increased yield of CMR in the
10 studies conducted in non-stroke populations (28.1 vs.
16.0%, P < 0.001, Supplementary Table 5). Non-thrombotic
masses, i.e., cardiac tumors were overall rare in stroke
populations. The same was true for valvular vegetations with
only anecdotal data reporting on the comparison of both
modalities (40).
Other Potential Sources of Embolism
Complex Aortic Plaques
Overall, the diagnostic yield of CMR and echocardiography
(almost exclusively TEE) to identify complex aortic plaque was
similar. Faber et al. showed that also the measurements of plaque
thickness correlated well in the aortic arch with CMR being
able to identify 89% of ulcerations in the proximal aorta seen
on TEE (22). Harloff et al. found that CMR in patients with
cryptogenic stroke had higher diagnostic yield in the detection
of aortic high risk plaques as compared to TEE (50 vs 31.1%, p=
0.029). In parallel, the absolute number of complex aortic plaques
and thrombi detected by CMR was higher than with TEE (74 vs.
47) (45).
Aortic Dissection
A meta-analysis found that TEE, and CMR had equally reliable
diagnostic yield for confirming or ruling out thoracic aortic
dissection (46). However, TTE was inferior (47).
Mitral Valve Stenosis
There was strong agreement between TTE and CMR for
quantification of mitral valve stenosis (limits of agreement for
valve area−0.13 to 0.09 cm2) (48–50).
Cardiomyopathies
CMR was found to have higher diagnostic yield in detecting
LV non-compaction cardiomyopathy as compared to TTE (51).
Similarly, Fonseca et al. reported that among 132 patients with
cryptogenic stroke, CMR was able to identify 7 patients with
undiagnosed cardiomyopathies (4 hypertrophic, 2 restrictive, one
non-compaction cardiomyopathy) (52).
Myocardial Infarction
CMR identified previous myocardial infarction in 13/89 (15%)
of cryptogenic stroke patients, with echocardiography being able
to pick up only 4/13 (31%) of those (31). Of note, only one
patient had clinical manifest acute coronary syndrome and two
previously known coronary artery disease.
Other Structural Findings With Potential
Management Consequence
LV Function
Häusler reported regional wall motion abnormalities in 4%
of cryptogenic stroke patients according to echocardiography,
but 12% according to CMR (31). Importantly, both systolic
and diastolic dysfunction can be assessed by CMR and
echocardiography, also in AIS patients (53, 54).
LA Volume and Function
In patients with permanent AF, correlations for TTE and CMR
were fair to moderate and TTE measurements had inferior intra-
and inter-observer agreement (55–57). However, CMR can be
considered the gold standard for LA volume assessment (58).
Atrial fibrosis was found more frequently using CMR in patients
with undetermined stroke etiology as compared to other specific
causes (13) and was shown to be independently associated
with LAA-thrombus and spontaneous echo contrast on TEE
(59). Bertelsen showed that various parameters including LA
volume, LA emptying fraction or LA strain assessed by CMR
feature tracking predicted risk of incident AF during follow-up
using implantable loop recorders (60). However, also LAA peak
Frontiers in Neurology | www.frontiersin.org 5 July 2021 | Volume 12 | Article 699838
Meinel et al. Cardiovascular MRI and Echocardiography in Stroke
FIGURE 1 | PRISMA flow diagram.
emptying velocity as measured by TEE was shown to predict
incident AF after cryptogenic stroke (61).
Feasibility and Reproducibility of CMR
Häusler et al. reported that 89/103 (86%) of AIS patients
completed the entire CMR protocol including late gadolinium
enhancement assessment (median duration 50min, median 3
days after stroke). The main reasons for abortion of CMR were
motion artifacts or inability to cooperate with multiple breath-
holds despite the fact that such patients were already excluded
at baseline (31). In contrast, 101/103 (98%) completed the TEE
procedure with only one patient unable to tolerate the probe.
Hellwig et al. reported that functional CMR could be obtained
in 75% of AIS patients (54). In a study by Harloff et al., all 74
selected patients were able to complete a 49min thoracic MR for
aortic assessment but without cardiac-specific sequences within
1 week after stroke. However, image quality was considered low
in 43%, moderate in 30% and good in 27% of sequences (45).
Zahuranec et al. reported that of 28 patients planned to undergo
CMR, only 20 could finally start the procedure and one additional
patient stopped the scanning because of claustrophobia and in
one CMR study image quality was severely affected by arrhythmia
(34). Liberman et al. report that 6 out of 115 patients had
uninterpretable CMR images (36). Takasugi et al. found that 42%
of Asian embolic stroke of undetermined source patients were
ineligible for CE-CMR due to severe renal dysfunction (58%),
metal implants and other reasons (8).
Häusler et al. reported overall poor agreement for
identification of relevant findings between CMR and
echocardiography (κ = 0.24) with values slightly higher
when concentrating on patients who had completed both
procedures (κ = 0.47) (31).
Stroke Etiology, Prognosis
Baher et al. concluded that CMR could identify evident or
possible cardiac embolic sources in 1 in 4 patients with
cryptogenic AIS after a non-diagnostic TTE, however CMR led
to a direct management change (initiation of anticoagulation)
in only 3 of 106 patients (23). Häusler et al. reported that
TEE could add substantial information for determining stroke
etiology in 11 (12%) of 93 patients with otherwise cryptogenic
stroke, as compared to CMR that did so in 9 (9%) patients. Those
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197 3 4 2.0% (0.06–4.0%) 1 0.5% (0–1.5%) 0.8791
- TEE Studies 20 1 0 0% 0 0%
- TTE Studies 75 1 4 5.3% (0.2–10.4%) 1 1.3% (0–3.9%)
- Studies combination 102 1 0 0% 0 0%
Left
ventricular thrombus
221 4 7 3.2% (0.9–5.5%) 11 5.0% (2.1–7.8%) 0.8460
- TEE Studies 44 2 2 4.5% (0–10.7%) 2 4.5% (0–10.7%)




102 1 0 0% 1 1.0% (0–2.9%)
Valvular vegetation 289 4 6 2.1% (0.4–3.7%) 6 2.1% (0.4–3.7%) 1.0
- TEE Studies 113 2 2 1.8% (0–4.2%) 2 1.8% (0–4.2%)
- TTE Studies 75 1 2 2.7% (0–6.3%) 3 4.0% (0–8.4%)
- Studies
using combination
101 1 1 1.0% (0–2.9%) 2 2.0% (0–4.7%)
Non-thrombotic
masses, e.g., tumor
197 3 0 0% 1 0.5% (0–1.5%) 0.9598
- TEE Studies 20 1 0 0% 0 0%
- TTE Studies 75 1 0 0% 1 1.3% (0–3.9%)
- Studies
using combination
102 1 0 0% 0 0%
Complex aortic plaques 295 5 55 18.6% (14.2–23.1%) 48 16.3%
(12.1–20%)
0.5546
- TEE Studies 118 3 50 42.4% (33.5–51.3%) 42 35.6%
(27.0–44.2%)
- TTE Studies 75 1 2 2.7% (0–6.3%) 0 0%
- Studies
using combination
102 1 3 2.9% (0–6.2%) 6 5.9% (1.3–10.4%)
Persistent foramen
ovale (all TEE)
246 5 132 53.7% (47.4–59.9%) 72 29.3%
(23.6–35.0%)
<0.001
CMR, cardiovascular MRI; CI, confidence interval; P, P-value for comparison of the diagnostic yield by McNemar test. Bold represents overall findings (TEE and TTE results combined).
findings were consistent in 80 (86%) between the modalities (31).
CMR—mainly by detection of unrecognized previous myocardial
infarction—led to change of management in 6 patients (aspirin
in one patient and high-dose statin therapy in five patients).
Liberman et al. reported that only one single cryptogenic
stroke patient out of 64 could be reclassified into another
stroke etiology group by use of CMR after TEE. CMR was
unable to overall reduce the percentage of cryptogenic stroke
patients (36).
DISCUSSION
With this systematic review and meta-analysis, we provide
estimates for the diagnostic yield of CMR as compared to
echocardiography for the most relevant pathologies in AIS
patients. Except for PFO and LV thrombus, the diagnostic yield
of both modalities does not seem to differ substantially. The
major problem with the available observational data is that
a true gold-standard is missing for many pathologies. This
also implies that the overall diagnostic yield represents a more
meaningful outcome parameter than sensitivity and specificity.
More importantly, the clinical benefit of the management
consequences of the diagnostic findings is uncertain. Even for
echocardiography, after decades of use in stroke work-up, there is
no high-level evidence actually proving any benefit in functional
outcome or prevention of recurrent cardiovascular events.
The dilemma of observational diagnostic studies is that the
scientific standards of interventional trials are not applied,
despite the fact that the tests carry significant therapeutic
consequences. If there is clinical equipoise between two
modalities, only a trial randomizing both diagnostic strategies
could elucidate the overall clinical impact of the complex
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downstream management consequences. Applying the highest
scientific standards to diagnostics has a huge potential to improve
the value of care, eliminate redundant testing and cost savings
(62). In themeantime, high-quality observational trials should try
to clarify the impact of the diagnostic modality on downstream
consequences such as secondary prevention.
In clinical practice, TTE is more often performed despite
the fact that TEE has been shown superior in identifying most
cardioaortic sources of embolism like PFO, LA thrombus and
aortic arch pathologies (63–65). This is probably due to the
risks and logistic constraints of TEE (66, 67). Moreover, routine
echocardiography shows no clear potential sources of embolism
in the great majority of stroke patients and has a low yield
to detect clinically actionable findings for secondary stroke
prevention (68). The low yield should be balanced against the risk
of futility. Some clinicians may even consider echocardiography
inappropriate in some stroke patients.
Yield of CMR and Echocardiography for
Specific Pathologies
In non-stroke settings, contrast-enhanced CMR is the gold-
standard for detection of LV thrombus (30, 33, 69, 70). Contrast-
enhanced transthoracic echocardiography can improve detection
rate of LV thrombus, but has low sensitivity for mural or
small thrombi (71). Nevertheless, echocardiography assessing
left ventricular wall motion abnormalities could be a useful
screening tool (71, 72). A history of myocardial infarction and
low ejection fraction are useful predictors for the presence of LV
thrombus (8). Importantly, CMR could have detect unrecognized
myocardial infarction (73). This has therapeutic consequences
since stroke patients have concomitant coronary artery disease
in up to 25% (74). Additionally, CMR was found to potentially
represent a useful tool differentiating true cardiac ischemia
from neurogenically stunned myocardium in AIS patients with
troponin elevation and select patients for urgent coronary
angiography (75).
Regarding the assessment of LV function and volumes, CMR
is considered the gold standard, although echocardiography
remains the most widely used modality (76, 77). Since
anticoagulation has no advantage over standard antiplatelet
therapy in AIS patients with reduced LV function, the
management consequences remain limited however (78). CMR
is able to identify inherited or acquired cardiomyopathies that
were missed by TTE in about 5% of patients with AIS (52). In
regional areas with prevalent Chagas disease, CMR is able to
identify left ventricle aneurysm and intracardiac thrombus in a
relevant number of patients (79).
Overall, our findings demonstrate that CMR is clearly inferior
to TEE in PFO detection. Given the benefits of closure trials,
this culprit should be looked for rigorously in patients qualifying
for closure. However, alternatively specific CMR protocols or
transcranial contrast neurosonography should be used to detect
PFO, when PFO closure would be considered and TEE is
unavailable (80). CMR seems a fair alternative to TEE for LA-
and LAA -thrombus identification with a pooled sensitivity and
specificity of 0.80 (CI 0.63–0.91) and 0.98 (CI 0.97–0.99) (81).
CMR can be considered the gold standard for assessment
of non-thrombotic masses (82). In stroke patients particularly,
CMR is useful for differentiating tumors from thrombi (83).
There is paucity of data on the diagnostic yield of CMR
for infectious endocarditis. So far, CMR plays not part in
establishing or excluding the diagnosis of infectious endocarditis
due to imaging problems of very small and highly mobile
valvular structures. If there is clinical suspicion for infectious
endocarditis, a TEE should be performed. For the follow-up
of chronic aortic dissection, CMR seems a suitable imaging
modality (84). Yet, in acute aortic dissection, the time advantage
favors CT-angiography.
Overall, CMR seems to have reasonable yield in detection
and monitoring of mitral valve stenosis. However, according to
the most recent guidelines, echocardiography is the preferred
method for diagnosing mitral stenosis (85).
Management Consequences, Feasibility,
and Reproducibility
Apart from high-risk sources of embolism, several structural
findings might have implications for AIS patients: LA size
and fibrosis increase the risk for paroxysmal AF, stroke and
can potentially optimize patient selection for long-term rhythm
monitoring strategies or trials of anticoagulation in patients with
atrial disease without provenAF (12, 60, 86, 87). However, similar
findings can also be assessed using echocardiography and the
clinical benefit of CMR in predicting paroxysmal AF needs to be
determined (88, 89).
Overall, there seem to be issues with the feasibility
and reproducibility of CMR in the acute stroke workflow.
Interestingly, a large number of screened patients were found
to be ineligible because of kidney disease and metal implants
and patient preference was not clearly in favor of CMR over
TEE (34). Current CMR protocols are mostly based on sequences
in the breathholding technique and most stroke patients have
difficulties with cooperation in the acute phase.
The available data are insufficient to derive definite
conclusions whether CMR is able to improve the classification
of stroke etiology over echocardiography. At least, the evidence-
based changes in secondary stroke prevention found in 6%
of cryptogenic stroke patients seems modest (31). Most
therapeutic changes were from moderate to high-dose statin
therapy, which is anyway recommended for many patients with
atherosclerotic disease and stroke due to new data (90). Other
management consequences reported in historical studies are
debatable nowadays (anticoagulation for PFO and complex
aortic plaques). Apfalter et al. concluded in their observational
non-randomized monocentric analysis, that CMR and cardiac
CT might represent a valid alternative to echocardiography to
predict stroke recurrence based on the presence of intracardiac
thrombus, vulnerable aortic plaque, cardiac tumors, and valvular
vegetation (25).
How to Choose the Best Imaging Modality
Until Better Evidence Is Available?
A score has been developed to identify patients with high yield of
additional TEE after TTE (91), but consensus is lacking. Different
recommendations for patient selection have been made without
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a high evidence level showing improved clinical outcomes
according to such an approach (19). The question is whether a
“one size fits all” approach benefits patients or a sophisticated
individualized decision is more beneficial. ESUS represents a
subcategory of ischemic cryptogenic stroke with non-lacunar
imaging features in stroke patients without an immediately
identifiable cause such as large vessel disease, significant
intracranial atherosclerosis, or high-risk cardioembolic source.
However, it is unlikely that cardiac work-up should differ
according to these categories since findings are expected to be
similar due to the shared risk factors.
Currently, CMR represents a diagnostic option in experienced
centers and cooperative patients with embolic stroke in the case
of non-discriminative echocardiography or a high suspicion for
intracardiac thrombus or concomitant coronary artery disease.
Furthermore, CMR might be used for work-up of a cardiac
mass seen on an echocardiography as well as in patients who
decline TEE or in case of medical reasons against TEE. If CMR
is performed, it is important to include all relevant sequences
for reliable detection of cardio-aortic sources of embolism and
protocols have been published for this purpose (92). Cardiac
CT might be a promising alternative to TEE, at least for the
detection of cardiac thrombi and aortic pathologies in AIS
patients (93, 94). However, due to missing data on outcome
events this approach—similar to CMR—requires further study in
prospective randomized diagnostic trials.
The difference in contrast media might also inform the choice
of imaging modality. For CMR, most often gadolinium-based
contrast agents are used. Their main limitations include impaired
renal function with nephrogenic systemic fibrosis in rare cases,
allergic reactions as well as pregnancy. However, the risk for
nephrogenic systemic fibrosis is minimal for non-ionic cyclic
gadolinium-based contrast medium even in patients with severe
renal impairment. The long-term health effects of an uptake
of small proportions of unchelated gadolinium into the brain
and other body parts are currently unknown (95). For cardiac
CT, contrast quantity is always high limiting its use in patients
with impaired renal function (especially in patients taking
metformin). Additionally, irradiation makes CT impossible in
pregnant women and problematic in younger patients (96).
There are big variations of costs and durations of each
procedure according to the procotol, use of contrast agent and
health care system, however, in most settings, TTE will be the
least expensive, followed by TEE, cardiac CT and CMR with a
duration of roughly 1 h for most exams.
Limitations
The studies included in the meta-analysis represent
heterogeneous, highly selected populations. Risk of bias
was high for most items. Most of the cardio-aortic sources of
embolism have no clear definition and data are lacking to support
evidence-based changes in management based on those findings.
Most studies used TTE, which hampers to draw conclusions
for TEE, however this also reflects clinical practice with low
rates of TEE use. Additionally, due to the restriction to studies
using both examinations, our findings only apply to centers
that have access and the capacity to perform both modalities. In
clinical practice, indications for selection of work-up modality
will be heterogeneous and differ among different institutions
and clinical settings, hence questioning the generalizability of
the findings. Complications of TEE and CMR (especially use of
contrast media) were not reported by most of the studies and
hence only discussed cursorily. The time required and cost of the
various diagnostic methods are not mentioned since the focus of
this study was on diagnostic findings and management.
CONCLUSIONS
Echocardiography and CMR seem to have similar diagnostic
yield for most cardioaortic sources of embolism except persistent
foramen ovale (higher yield in echocardiography) and left
ventricular thrombus (higher yield in CMR). In order to
be used routinely in clinical practice, CMR has to prove
that it adds value to identification of high-risk sources of
embolism, is feasible in the AIS setting, and—most importantly—
improves clinical outcome events by prompting evidence-
based downstream therapeutic consequences in a cost-effective
manner. The next generation of stroke researchers should apply
the quality standards of interventional trials using randomization
and clinical outcomes to the diagnostic tests used in stroke
comparing the available diagnostic imaging modalities (TTE,
TEE, cardiac CT, CMR). Until this effort has been made,
echocardiography will remain the cornerstone of cardiac workup.
CMR represents an alternative in experienced centers, but faces
problems of feasibility.
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